Literature DB >> 26784936

Synthesis and Characterization of Fatty Acid Conjugates of Niacin and Salicylic Acid.

Chi B Vu1, Jean E Bemis1, Ericka Benson1, Pradeep Bista1, David Carney1, Richard Fahrner1, Diana Lee1, Feng Liu1, Pallavi Lonkar1, Jill C Milne1, Andrew J Nichols1, Dominic Picarella1, Adam Shoelson1, Jesse Smith1, Amal Ting1, Allison Wensley1, Maisy Yeager1, Michael Zimmer1, Michael R Jirousek1.   

Abstract

This report describes the synthesis and preliminary biological characterization of novel fatty acid niacin conjugates and fatty acid salicylate conjugates. These molecular entities were created by covalently linking two bioactive molecules, either niacin or salicylic acid, to an omega-3 fatty acid. This methodology allows the simultaneous intracellular delivery of two bioactives in order to elicit a pharmacological response that could not be replicated by administering the bioactives individually or in combination. The fatty acid niacin conjugate 5 has been shown to be an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1. On the other hand, the fatty acid salicylate conjugate 11 has been shown to have a unique anti-inflammatory profile based on its ability to modulate the NF-κB pathway through the intracellular release of the two bioactives.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26784936     DOI: 10.1021/acs.jmedchem.5b01961

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.

Authors:  Gabrielle N Winston-McPherson; Haibo Xie; Ka Yang; Xiaoxun Li; Dongxu Shu; Weiping Tang
Journal:  Bioorg Med Chem Lett       Date:  2019-06-12       Impact factor: 2.823

2.  Disease-modifying effects of orally bioavailable NF-κB inhibitors in dystrophin-deficient muscle.

Authors:  David W Hammers; Margaret M Sleeper; Sean C Forbes; Cora C Coker; Michael R Jirousek; Michael Zimmer; Glenn A Walter; H Lee Sweeney
Journal:  JCI Insight       Date:  2016-12-22

3.  CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice.

Authors:  Michael Zimmer; Pradeep Bista; Ericka L Benson; Diana Y Lee; Feng Liu; Dominic Picarella; Rick B Vega; Chi B Vu; Maisy Yeager; Min Ding; Guosheng Liang; Jay D Horton; Robert Kleemann; Teake Kooistra; Martine C Morrison; Peter Y Wielinga; Jill C Milne; Michael R Jirousek; Andrew J Nichols
Journal:  Hepatol Commun       Date:  2017-05-12

4.  A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.

Authors:  Joanne M Donovan; Michael Zimmer; Elliot Offman; Toni Grant; Michael Jirousek
Journal:  J Clin Pharmacol       Date:  2017-01-11       Impact factor: 3.126

5.  α-Linolenic Acid-Valproic Acid Conjugates: Toward Single-Molecule Polypharmacology for Multiple Sclerosis.

Authors:  Michele Rossi; Sabrina Petralla; Michele Protti; Monica Baiula; Tereza Kobrlova; Ondrej Soukup; Santi Mario Spampinato; Laura Mercolini; Barbara Monti; Maria Laura Bolognesi
Journal:  ACS Med Chem Lett       Date:  2020-10-27       Impact factor: 4.345

6.  From Combinations to Single-Molecule Polypharmacology-Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease.

Authors:  Claudia Albertini; Marina Naldi; Sabrina Petralla; Silvia Strocchi; Daniela Grifoni; Barbara Monti; Manuela Bartolini; Maria Laura Bolognesi
Journal:  Molecules       Date:  2021-02-19       Impact factor: 4.411

Review 7.  Drug development progress in duchenne muscular dystrophy.

Authors:  Jiexin Deng; Junshi Zhang; Keli Shi; Zhigang Liu
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

8.  Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.

Authors:  Erika Finanger; Krista Vandenborne; Richard S Finkel; H Lee Sweeney; Gihan Tennekoon; Sabrina Yum; Maria Mancini; Pradeep Bista; Andrew Nichols; Hanlan Liu; Angelika Fretzen; Joanne M Donovan
Journal:  J Neuromuscul Dis       Date:  2019
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.